AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36030811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (asynchronous online consultation, 200 mg mifepristone and 800 μg misoprostol at home)
Number of subjects: 900
Study 36030811 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (in-person consultation, 200 mg mifepristone in clinic and 800 μg misoprostol at home)
Number of subjects: 900
Study 33270092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0
Study 33270092 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36045818 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of rectal misoprostol
Number of subjects: 128
Study 36045818 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg of sublingual misoprostol
Number of subjects: 128
Study 36045818 — intervention group
Group type: COMPARATOR
Intervention: 30 units of oxytocin (control)
Number of subjects: 128
Study 35666231 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 26.1/5.2 mg (Treatment A)
Number of subjects: 23
Study 35666231 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 39.2/7.8 mg (Treatment B)
Number of subjects: 23
Study 35666231 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 52.3/10.4 mg (Treatment C)
Number of subjects: 23
Study 35666231 — intervention group
Group type: EXPERIMENTAL
Intervention: SDX/d-MPH 52.3/10.4 mg (multiple dosing)
Number of subjects: 23
Study 33767064 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (specific types not mentioned)
Number of subjects: 5868
Study 33767064 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (dapagliflozin)
Number of subjects: 5868
Study 33767064 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (empagliflozin)
Number of subjects: 5868
Study 33767064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5868
Study 35807922 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Protein (GP) diet (0.8 g/kg/d at week 1 to 2.2 g/kg/d at week 10 with whey protein supplement)
Number of subjects: 18
Study 35807922 — intervention group
Group type: COMPARATOR
Intervention: Constant Protein (CP) diet (0.8-1.0 g/kg/d with no protein supplement)
Number of subjects: 18
Study 34849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Building Up Trial intervention
Number of subjects: 225
Study 33206251 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐intensity aerobic training (MOD T)
Number of subjects: 45
Study 33206251 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic training (HIGH T)
Number of subjects: 45
Study 33206251 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study 32453870 — intervention group
Group type: EXPERIMENTAL
Intervention: pep_RTE62G
Number of subjects: 0
Study 33715655 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid alloy 80% Cu-20% Ni (integral copper)
Number of subjects: 480
Study 33715655 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray-on 80% Cu-20% Ni (spray-on)
Number of subjects: 480
Study 33715655 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% composite copper-impregnated surface (CIS)
Number of subjects: 480
Study 33715655 — intervention group
Group type: COMPARATOR
Intervention: Control surgical grade (AISI 316) stainless steel
Number of subjects: 480
Study 34412070 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib treatment
Number of subjects: 0
Study 34412070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cdc42/Rac1 inhibition
Number of subjects: 0
Study 34412070 — intervention group
Group type: EXPERIMENTAL
Intervention: PAK1 downregulation
Number of subjects: 0
Study 33142773 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign Language Learning (FLL)
Number of subjects: 105
Study 33142773 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Young Adults)
Number of subjects: 105
Study 33142773 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Elderly)
Number of subjects: 105
Study 36007980 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol
Number of subjects: 648
Study 36007980 — intervention group
Group type: COMPARATOR
Intervention: Maintenance budesonide plus SABA
Number of subjects: 648
Study 33853098 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massages
Number of subjects: 66
Study 35511858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 1343
Study 35511858 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric restriction (NoCR)
Number of subjects: 1343
Study 35511858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) with exercise
Number of subjects: 1343
Study 33780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin pessary in addition to standard care (n=250)
Number of subjects: 503
Study 33780463 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (n=253)
Number of subjects: 503
Study 33780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary (meta-analysis of 4 studies, 313 women)
Number of subjects: 503
Study 33780463 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin pessary group (n=250)
Number of subjects: 503
Study 33780463 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (n=253)
Number of subjects: 503
Study 33079877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous invasive arterial pressure monitoring
Number of subjects: 152
Study 33079877 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oscillometric blood pressure monitoring
Number of subjects: 152
Study 35581710 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane (ESP) Block
Number of subjects: 60
Study 35581710 — intervention group
Group type: COMPARATOR
Intervention: Transversus Abdominis Plane (TAP) Block
Number of subjects: 60
Study 33888542 — intervention group
Group type: EXPERIMENTAL
Intervention: Famine-exposed group (1959-1962)
Number of subjects: 2171
Study 32954927 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus endocrine therapy (ET)
Number of subjects: 5637
Study 32954927 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone
Number of subjects: 5637
Study 34931699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led interdisciplinary intervention
Number of subjects: 221
Study 34339598 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan for 48 weeks
Number of subjects: 220
Study 34339598 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 48 weeks
Number of subjects: 220
Study 35120288 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/d)
Number of subjects: 45
Study 35120288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33027550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity hybrid-functional electrical stimulation rowing for 6 months
Number of subjects: 40
Study 36414580 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti Technique
Number of subjects: 104
Study 36414580 — intervention group
Group type: COMPARATOR
Intervention: Standard Ponseti Technique
Number of subjects: 104
Study 32076698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low density lipoprotein (LDL)-cholesterol
Number of subjects: 432173
Study 32076698 — intervention group
Group type: EXPERIMENTAL
Intervention: High density lipoprotein (HDL)-cholesterol
Number of subjects: 432173
Study 32076698 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 432173
Study 32076698 — intervention group
Group type: COMPARATOR
Intervention: Negative control outcomes (aortic regurgitation and mitral regurgitation)
Number of subjects: 432173
Study 35475948 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (particle mass concentrations around 300 µg/m3)
Number of subjects: 18
Study 35475948 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure to diesel exhaust and high traffic noise (75 dB(A))
Number of subjects: 18
Study 35475948 — intervention group
Group type: COMPARATOR
Intervention: Filtered (clean) air exposure
Number of subjects: 18
Study 35475948 — intervention group
Group type: COMPARATOR
Intervention: Noise exposure only (46 dB(A))
Number of subjects: 18
Study 33325216 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation strategy (G1)
Number of subjects: 100
Study 33325216 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation strategy (G0)
Number of subjects: 100
Study 34410203 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT treatment
Number of subjects: 48
Study 34188527 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-VG
Number of subjects: 64
Study 34188527 — intervention group
Group type: COMPARATOR
Intervention: VCV
Number of subjects: 64
Study 36471268 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and Brief Intervention (SBI)
Number of subjects: 330
Study 36471268 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition (AC)
Number of subjects: 330
Study 33884269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer position between the tracheal tube and Y‐piece (Group A)
Number of subjects: 75
Study 33884269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer position at the inspiratory limb near the ventilator water cup (Group B)
Number of subjects: 75
Study 33884269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer position between the ventilator inlet and the heated humidifier (Group C)
Number of subjects: 75
Study 35301888 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin monotherapy
Number of subjects: 63
Study 35301888 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin/ezetimibe combination therapy
Number of subjects: 63
Study 34268884 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metformin (1 g) with codeine (25 mg)
Number of subjects: 0
Study 34268884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metformin (0.5 g) with codeine (25 mg)
Number of subjects: 0
Study 34268884 — intervention group
Group type: COMPARATOR
Intervention: Oral metformin (1 g) without codeine
Number of subjects: 0
Study 34268884 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metformin (0.5 g) without codeine
Number of subjects: 0
Study 32964756 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure dressing
Number of subjects: 0
Study 32964756 — intervention group
Group type: COMPARATOR
Intervention: Standard care (fixation strips)
Number of subjects: 0
Study 34743319 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 mg daily for 7 days, then 20 mg daily for 7 days)
Number of subjects: 0
Study 34743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (14 days before psilocybin administration)
Number of subjects: 0
Study 34743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 0
Study 34743319 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and Psilocybin
Number of subjects: 0
Study 35777867 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (1 month) followed by cognitive training (1 month)
Number of subjects: 81
Study 35777867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (1 month) followed by physical activity (1 month)
Number of subjects: 81
Study 35777867 — intervention group
Group type: EXPERIMENTAL
Intervention: Active breathing condition (psychoeducation and resonance frequency breathing for 1 month) followed by combined physical activity and cognitive training (1 month)
Number of subjects: 81
Study 35777867 — intervention group
Group type: COMPARATOR
Intervention: Wash-out periods (15 days) between interventions
Number of subjects: 81
Study 32026495 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMU method
Number of subjects: 162
Study 32026495 — intervention group
Group type: COMPARATOR
Intervention: Weight-based equation
Number of subjects: 162
Study 34423676 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (with a 7-day lead-in at 90 mg once daily)
Number of subjects: 0
Study 34423676 — intervention group
Group type: COMPARATOR
Intervention: Alectinib 600 mg twice daily
Number of subjects: 0
Study 32660347 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mA stimulation
Number of subjects: 23
Study 34718628 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (≥ 0.15 mg/kg/day)
Number of subjects: 10
Study 34718628 — intervention group
Group type: COMPARATOR
Intervention: Control (no metreleptin)
Number of subjects: 10
Study 32978119 — intervention group
Group type: COMPARATOR
Intervention: Dry standard retinoscopy
Number of subjects: 39
Study 32978119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirza tele-lens retinoscopy
Number of subjects: 39
Study 32978119 — intervention group
Group type: COMPARATOR
Intervention: Cycloplegic standard retinoscopy
Number of subjects: 39
Study 32978119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloplegic Mirza tele-lens retinoscopy
Number of subjects: 39
Study 32978119 — intervention group
Group type: COMPARATOR
Intervention: Dry retinoscopy methods
Number of subjects: 39
Study 32978119 — intervention group
Group type: COMPARATOR
Intervention: Cyclo retinoscopy methods
Number of subjects: 39
Study 32039739 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation training in addition to care as usual (multidisciplinary obesity treatment)
Number of subjects: 140
Study 32039739 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (multidisciplinary obesity treatment)
Number of subjects: 140
Study 34138499 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane (Bio‐Gide) used in regenerative endodontics
Number of subjects: 80
Study 34138499 — intervention group
Group type: COMPARATOR
Intervention: No collagen membrane used in regenerative endodontics
Number of subjects: 80
Study 34283037 — intervention group
Group type: EXPERIMENTAL
Intervention: MT‐Phoenix (gamified smartphone-based intervention)
Number of subjects: 77
Study 34283037 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 77
Study 32583907 — intervention group
Group type: EXPERIMENTAL
Intervention: Minesapride 10 mg/d
Number of subjects: 411
Study 32583907 — intervention group
Group type: EXPERIMENTAL
Intervention: Minesapride 20 mg/d
Number of subjects: 411
Study 32583907 — intervention group
Group type: EXPERIMENTAL
Intervention: Minesapride 40 mg/d
Number of subjects: 411
Study 32583907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 36142073 — intervention group
Group type: EXPERIMENTAL
Intervention: Circling Curriculum for Metacognition Training (CCMT)
Number of subjects: 47
Study 36142073 — intervention group
Group type: COMPARATOR
Intervention: Routine teaching activities (Control)
Number of subjects: 47
Study 34455152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral continuous T8 ESP blocks with a programmed intermittent bolus regimen of 10 mL 0.2% ropivacaine every 3 h for 48 h (n=30)
Number of subjects: 60
Study 34455152 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) 400 μg (n=30)
Number of subjects: 60
Study 35709415 — intervention group
Group type: COMPARATOR
Intervention: FLOT alone (arm A)
Number of subjects: 81
Study 35709415 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT with trastuzumab and pertuzumab (arm B)
Number of subjects: 81
Study 32037195 — intervention group
Group type: EXPERIMENTAL
Intervention: Demcizumab (DLL4 targeted IgG2 humanized monoclonal antibody) combined with paclitaxel (2.5 mg/kg and 5 mg/kg doses); administered on days 1 and 15 for 3 cycles, followed by paclitaxel until unacceptable toxicity or disease progression.
Number of subjects: 19
Study 35319005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based sports beverage (RB)
Number of subjects: 18
Study 35319005 — intervention group
Group type: COMPARATOR
Intervention: Sucrose-based sports beverage (SB)
Number of subjects: 18
Study 34819150 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral quadratus lumborum block (QLB) with 0.375% bupivacaine 0.5 mL/kg (QLB group)
Number of subjects: 56
Study 34819150 — intervention group
Group type: COMPARATOR
Intervention: Conventional scheme (control group)
Number of subjects: 56
Study 34819150 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral quadratus lumborum block (QLB)
Number of subjects: 56
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab or Bevacizumab (protocol-guided treatment)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse visual acuity (20/200-20/320)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger neovascularization area (>4 disc areas)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Switched drug regimen
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants ARMS2 (TT variant)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants HTRA1 (AG variant)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants HTRA1 (AA variant)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-retinal pigment epithelium thickness (>275 μm)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse fellow-eye visual acuity (<20/40)
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow-eye GA
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudodrusen in either eye
Number of subjects: 1107
Study 32191267 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal fluid
Number of subjects: 1107
Study 33943011 — intervention group
Group type: EXPERIMENTAL
Intervention: S + POCT (surgery plus postoperative chemotherapy)
Number of subjects: 782
Study 33943011 — intervention group
Group type: COMPARATOR
Intervention: S (surgery alone)
Number of subjects: 782
Study 32919288 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-water imaging in early course schizophrenia
Number of subjects: 79
Study 35459106 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery intervention (listened to audio file for 25 min at home)
Number of subjects: 60
Study 35459106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 33744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole
Number of subjects: 1499
Study 33744963 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chloroquine
Number of subjects: 1499
Study 33744963 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 1499
Study 35779599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated gradients
Number of subjects: 104
Study 33901547 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric device
Number of subjects: 40
Study 33901547 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgical carbide burs and curettes)
Number of subjects: 40
Study 32466923 — intervention group
Group type: EXPERIMENTAL
Intervention: High hedonic rating of porcini mushrooms due to aroma notes (seasoning-like, roasted, cacao-like, smoky)
Number of subjects: 0
Study 32466923 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hedonic liking of porcini mushrooms due to raw mushroom-like, cardboard-like, sweaty attributes
Number of subjects: 0
Study 35278693 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Adherence Enhancement for Adolescents and Young Adults (CAE‐AYA)
Number of subjects: 40
Study 35278693 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 40
Study 32170754 — intervention group
Group type: COMPARATOR
Intervention: DeepMedic, 3D U-Net, V-Net, Dense V-Net
Number of subjects: 38
Study 34181360 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg VLX-ER
Number of subjects: 310
Study 34181360 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg VLX-ER
Number of subjects: 310
Study 34181360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 32396775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 529
Study 32396775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 33045861 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Information Sheets (PIS)
Number of subjects: 50
Study 33045861 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent Forms (CF)
Number of subjects: 50
Study 32959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular or yearly influenza vaccination uptake among students (10.2%), patients (19.1%), and HCWs (35.6%).
Number of subjects: 247
Study 32959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Having children as a predictor of vaccination uptake (adjusted OR = 3.8; 95% CI 1.2‐12.5).
Number of subjects: 247
Study 32959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported level of knowledge as a predictor of vaccination uptake (OR = 16.3; 95% CI 1.4‐194.2).
Number of subjects: 247
Study 32959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of consequences of influenza as a barrier (OR = 0.2; 95% CI 0.1‐0.6).
Number of subjects: 247
Study 32959616 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to vaccination include lack of information (31%), fear of adverse effects (29%), and perception of not being at risk (23%).
Number of subjects: 247
Study 34261196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training in the workplace
Number of subjects: 608
Study 34249487 — intervention group
Group type: EXPERIMENTAL
Intervention: PIT tags
Number of subjects: 200
Study 34249487 — intervention group
Group type: COMPARATOR
Intervention: Control (untagged)
Number of subjects: 200
Study 33759038 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HCT) in refractory MS
Number of subjects: 0